Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Emerging potential of spatial genomic analysis as cancer diagnostic tool
4.2.2 Emerging players can boost the market competitiveness
4.2.3 Advent of fourth generation of sequencing
4.3 Market Restraints
4.3.1 Slow implementation of technology
4.3.2 Well-established workflows for conventional genomics & transcriptomics analysis
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Spatial Transcriptomics
5.1.1.1 Sequencing-Based Methods
5.1.1.2 IHC
5.1.1.3 Microscopy-based RNA Imaging Techniques
5.1.2 Spatial Genomics
5.1.2.1 Microscopy-based Live DNA Imaging
5.1.2.2 FISH
5.1.2.3 Massively-Parallel Sequencing
5.1.2.4 Genome Perturbation Tools
5.1.2.5 Biochemical Techniques
5.1.2.6 Others
5.2 By Product
5.2.1 Instruments
5.2.2 Software
5.2.3 Consumables
5.3 By End-User
5.3.1 Pharmaceutical Manufacturer
5.3.2 Academic Customers
5.3.3 Diagnostic Customers
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 10x Genomics
6.1.2 SPATIAL TRANSCRIPTOMICS
6.1.3 Dovetail Genomics
6.1.4 Illumina, Inc.
6.1.5 S2 Genomics, Inc.
6.1.6 NanoString Technologies, Inc.
6.1.7 Seven Bridges Genomics
6.1.8 Horizon Discovery Group plc
6.1.9 Advanced Cell Diagnostics, Inc. (ACD)
6.1.10 CARTANA AB


7 MARKET OPPORTUNITIES AND FUTURE TRENDS